Adverse events, OHSS, preterm delivery, congenital anomaly · women with gonadotropin plus oral (clomiphene citrate or letrozole) stimulation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, OHSS, preterm delivery, congenital anomaly · women with oral (clomiphene citrate or letrozole) stimulation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, OHSS, preterm delivery, congenital anomaly · women trying to conceive by intrauterine insemination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events, OHSS, preterm delivery, congenital anomaly · women trying to conceive by intrauterine insemination
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults with trichotillomania
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
It is very uncertain whether induced hypertension changes proportion of participants with ≥ 1 serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments
Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).
1 finding from 1 review
SAEs · psoriatic arthritis
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Adverse Events ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma‐related non‐fatal serious adverse events ‐ children · patients with chronic asthma
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (timing not specified) · exacerbations of COPD
Antibiotics showed no clear difference in adverse events ‐ overall (any adverse events not specified) compared with placebo overall (moderate certainty).
1 finding from 1 review
Adverse events ‐ conjunctival blanching during study period · people with glaucoma receiving LTP
1 finding from 1 review
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events ‐ Miscarriage · women with subfertility
Antioxidant(s) showed no clear difference in adverse events ‐ Miscarriage№ of participants: 3229(24 RCTs) compared with placebo or no treatment/standard treatment (low certainty).
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with atopic dermatitis
1 finding from 1 review
Minor adverse events not leading to withdrawal of treatment · people with atopic dermatitis
Bleach bath showed no clear difference in minor adverse events not requiring withdrawal from treatment compared with placebo or bath emollient (low certainty).
1 finding from 1 review
Adverse events of glucocorticoids and immunosuppressive drugs · people with focal epilepsy
Immunomodulatory interventions may leads to higher adverse events of glucocorticoids and immunosuppressive drugs compared with placebo (low certainty).
1 finding from 1 review
Mortality or serious adverse events requiring hospital admission · Adults or children at increased risk of bacterial endocarditis (pre-existing cardiac condition) undergoing an invasive dental procedure
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events (grade ≥ 3) · people with a primary brain tumour
1 finding from 1 review